Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Liabilities and Shareholders Equity (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Liabilities and Shareholders Equity data on record, last reported at $11.0 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 23.63% year-over-year to $11.0 million; the TTM value through Sep 2025 reached $44.6 million, down 33.25%, while the annual FY2024 figure was $12.1 million, 34.85% down from the prior year.
  • Liabilities and Shareholders Equity reached $11.0 million in Q3 2025 per GANX's latest filing, up from $9.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $48.0 million in Q1 2021 and bottomed at $9.8 million in Q2 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $24.3 million, with a median of $19.2 million recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 305.91% in 2021, then crashed 50.23% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $39.0 million in 2021, then tumbled by 38.18% to $24.1 million in 2022, then fell by 22.78% to $18.6 million in 2023, then tumbled by 34.85% to $12.1 million in 2024, then dropped by 9.5% to $11.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $11.0 million in Q3 2025, $9.8 million in Q2 2025, and $11.6 million in Q1 2025.